Evercore ISI raised the firm’s price target on Baxter to $58 from $55 and keeps an Outperform rating on the shares, which the analyst is also adding to the firm’s “Tactical Outperform” list ahead of earnings from the MedTech, Life Science Tools and Diagnostics group. Evercore has “a distinct bias towards mega caps and value/GARP as we head into” Q2, the analyst tells investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on BAX: